Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinqiao Baiyi Fang (银翘败疫方) is a Traditional Chinese Medicine (TCM) decoction developed by the First Affiliated Hospital to Henan University of Chinese Medicine for the treatment of mild COVID-19. The formula is based on classic TCM principles for clearing heat and detoxifying, specifically targeting epidemic respiratory diseases. The name 'Yinqiao' suggests the inclusion of *Lonicera japonica* (honeysuckle) and *Forsythia suspensa*, which are standard botanical components in anti-viral TCM prescriptions. The efficacy and safety of the decoction were evaluated in a randomized, open-label, controlled clinical trial (ChiCTR2200065467) to assess its impact on clinical symptom relief and viral clearance in patients with mild SARS-CoV-2 infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinqiao Baiyi Fang.